Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LT-02 vs placebo vs mesalamine for maintenance of remission in ulcerative colitis
2013-001205-84Phase 3Completed
- Sponsor
- Dr. Falk Pharma GmbH
- Start
- Aug 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of phosphatidylcholine (LT-02) in autoimmune colitis (3 arms), sponsored by Dr. Falk Pharma GmbH. Primary endpoint: Relapse-free and non-treatment failure rate at 48 weeks. Started Aug 2014; status: completed.
02
Drugs
phosphatidylcholine (LT-02)
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2013-001205-84.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-001205-84.